In a recent study published in Nature, Breart et al.1 untangled the controversy surrounding interleukin (IL)-27’s role in regulating T cell differentiation and immune responses in cancer. Their findings reveal that IL-27 enhances the persistence and effector functions of tumor-infiltrating CD8+ T lymphocytes (TILs), preventing exhaustion, sustaining T cell-dependent tumor control and immunotherapy efficacy without significant systemic side effects.
IL-27: overclocking cytotoxic T lymphocytes to boost cancer immunotherapy
Bronte, Vincenzo
;De Sanctis, Francesco
2025-01-01
Abstract
In a recent study published in Nature, Breart et al.1 untangled the controversy surrounding interleukin (IL)-27’s role in regulating T cell differentiation and immune responses in cancer. Their findings reveal that IL-27 enhances the persistence and effector functions of tumor-infiltrating CD8+ T lymphocytes (TILs), preventing exhaustion, sustaining T cell-dependent tumor control and immunotherapy efficacy without significant systemic side effects.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
s41392-025-02212-z (1).pdf
accesso aperto
Licenza:
Creative commons
Dimensione
904.56 kB
Formato
Adobe PDF
|
904.56 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
